Gestational diabetes and hypertensive disorders of pregnancy as vascular risk signals: An overview and grading of the evidence

Canadian Journal of Cardiology

Volumn 30, Issue 7, 2014, Pages 765-773

  Nerenberg, Kara ^a   Daskalopoulou, Stella S ^b,c   Dasgupta, Kaberi ^b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; CELL ADHESION MOLECULE; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN; INTEGRIN; PLACENTAL GROWTH FACTOR; SERINE PROTEINASE INHIBITOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELL INVASION; CHROMOSOME ABERRATION; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; GENETIC VARIABILITY; HEALTH CARE UTILIZATION; HIGH RISK PREGNANCY; HUMAN; IMMUNE RESPONSE; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; LEUKOCYTE ACTIVATION; LIFESTYLE MODIFICATION; LIPID METABOLISM; MATERNAL HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHAGOCYTOSIS; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PUERPERIUM; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SLEEP DISORDERED BREATHING; TROPHOBLAST; VASCULAR DISEASE;

BLOOD PRESSURE; DIABETES, GESTATIONAL; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; WORLD HEALTH;

EID: 84903196055     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.12.030     Document Type: Review

References (96)

1. Pilote L., Dasgupta K., Guru V., et al. Acomprehensive view of sex-specific issues related to cardiovascular disease. CMAJ 2007, 176:S1-44.
2. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee Diabetes and Pregnancy. Can J Diabetes 2013, 37:S168-S183.
3. Kaaja R., Ronnemaa T. Gestational diabetes: pathogenesis and consequences to mother and offspring. Rev Diabet Stud 2008, 5:194-202.
4. Nerenberg K.A., Johnson J.A., Leung B., et al. Risks of gestational diabetes and preeclampsia over the last decade in a cohort of Alberta women. J Obstet Gynaecol Can 2013, 35:986-994.
5. Metzger B.E., Lowe L.P., Dyer A.R., et al. Hyperglycemia and adverse pregnancy outcomes. NEngl J Med 2008, 358:1991-2002.
6. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia. Lancet 2005, 365:785-799.
7. Maynard S.E., Karumanchi S.A. Angiogenic factors and preeclampsia. Semin Nephrol 2011, 31:33-46.
8. Steegers E.A., von D.P., Duvekot J.J., Pijnenborg R. Pre-eclampsia. Lancet 2010, 376:631-644.
9. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008, 51:970-975.
10. Meekins J.W., Pijnenborg R., Hanssens M., McFadyen I.R., van Asshe A. Astudy of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994, 101:669-674.
11. Zhou Y., McMaster M., Woo K., et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002, 160:1405-1423.
12. Clark D.E., Smith S.K., He Y., et al. Avascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998, 59:1540-1548.
13. Mistry H.D., Kurlak L.O., Broughton P.F. The placental renin-angiotensin system and oxidative stress in pre-eclampsia. Placenta 2013, 34:182-186.
14. Granger J.P., Alexander B.T., Bennett W.A., Khalil R.A. Pathophysiology of pregnancy-induced hypertension. Am J Hypertens 2001, 14:178S-185S.
15. Buurma A.J., Turner R.J., Driessen J.H., et al. Genetic variants in pre-eclampsia: a meta-analysis. Hum Reprod Update 2013, 19:289-303.
16. Ahn H., Park J., Gilman-Sachs A., Kwak-Kim J. Immunologic characteristics of preeclampsia, a comprehensive review. Am J Reprod Immunol 2011, 65(4):377-394.
17. Genbacev O., DiFederico E., McMaster M., Fisher S.J. Invasive cytotrophoblast apoptosis in pre-eclampsia. Hum Reprod 1999, 14(suppl 2):59-66.
18. Uzan J., Carbonnel M., Piconne O., Asmar R., Ayoubi J.M. Pre-eclampsia: pathophysiology, diagnosis, and management. Vasc Health Risk Manag 2011, 7:467-474.
19. Redman C.W., Sacks G.P., Sargent I.L. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999, 180:499-506.
20. Lynch A.M., Murphy J.R., Gibbs R.S., et al. The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG 2010, 117:456-462.
21. Ramma W., Ahmed A. Is inflammation the cause of pre-eclampsia?. Biochem Soc Trans 2011, 39:1619-1627.
22. Germain S.J., Sacks G.P., Sooranna S.R., Sargent I.L., Redman C.W. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. JImmunol 2007, 178:5949-5956.
23. Redman C.W., Tannetta D.S., Dragovic R.A., et al. Review: does size matter? Placental debris and the pathophysiology of pre-eclampsia. Placenta 2012, 33:S48-S54.
24. Powe C.E., Levine R.J., Karumanchi S.A. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011, 123:2856-2869.
25. Romero R., Nien J.K., Espinoza J., et al. Alongitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. JMatern Fetal Neonatal Med 2008, 21:9-23.
26. Fisher S.J. The placental problem: linking abnormal cytotrophoblast differentiation to the maternal symptoms of preeclampsia. Reprod Biol Endocrinol 2004, 2:53.
27. Venkatesha S., Toporsian M., Lam C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006, 12:642-649.
28. Grill S., Rusterholz C., Zanetti-Dallenbach R., et al. Potential markers of preeclampsia-a review. Reprod Biol Endocrinol 2009, 7:70.
29. Mutter W.P., Karumanchi S.A. Molecular mechanisms of preeclampsia. Microvasc Res 2008, 75:1-8.
30. Staff A.C., Dechend R., Pijnenborg R. Learning from the placenta: acute atherosis and vascular remodeling in preeclampsia-novel aspects for atherosclerosis and future cardiovascular health. Hypertension 2010, 56:1026-1034.
31. Hladunewich M., Karumanchi S.A., Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol 2007, 2:543-549.
32. Altman D., Carroli G., Duley L., et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002, 359:1877-1890.
33. Society of Obstetricians and Gynaecologists of Canada (SOGC) Hypertension and pregnancy guidelines. JObstet Gynaecol Can 2008, 30:1-52.
34. Feig D.S., Zinman B., Wang X., Hux J.E. Risk of development of diabetes mellitus after diagnosis of gestational diabetes [Erratum in: CMAJ. 2008 Aug 12;179(4):344.]. CMAJ 2008 July 29, 179(3):229-234.
35. Anna V., van der Ploeg H.P., Cheung N.W., Huxley R.R., Bauman A.E. Sociodemographic correlates of the increasing trend in prevalence of gestational diabetes mellitus in a large population of women between 1995 and 2005. Diabetes Care 2008, 31:2288-2293.
36. Joseph K.S., Liston R.M., Dodds L., Dahlgren L., Allen A.C. Socioeconomic status and perinatal outcomes in a setting with universal access to essential health care services. CMAJ 2007, 177:583-590.
37. Conde-Agudelo A., Belizan J.M. Risk factors for pre-eclampsia in a large cohort of Latin American and Caribbean women. BJOG 2000, 107:75-83.
38. Steinfeld J.D., Valentine S., Lerer T., et al. Obesity-related complications of pregnancy vary by race. JMatern Fetal Med 2000, 9:238-241.
39. Hedderson M.M., Darbinian J.A., Ferrara A. Disparities in the risk of gestational diabetes by race-ethnicity and country of birth. Paediatr Perinat Epidemiol 2010, 24:441-448.
40. Miranda M.L., Swamy G.K., Edwards S., et al. Disparities in maternal hypertension and pregnancy outcomes: evidence from North Carolina, 1994-2003. Public Health Rep 2010, 125:579-587.
41. Brewster L.M., Taherzadeh Z., Volger S., et al. Ethnic differences in resistance artery contractility of normotensive pregnant women. Am J Physiol Heart Circ Physiol 2010, 299:H431-H436.
42. Pamidi S., Pinto L.M., Marc I., et al. Maternal sleep-disordered breathing and adverse pregnancy outcomes - a systematic review and meta-analysis. Am J Obstet Gynecol 2014, 210:52.e1-52.e14.
43. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. NEngl J Med 2004, 350:672-683.
44. Dabelea D., Snell-Bergeon J.K., Hartsfield C.L., et al. Increasing prevalence of gestational diabetes mellitus (GDM) over time and by birth cohort: Kaiser Permanente of Colorado GDM Screening Program. Diabetes Care 2005, 28:579-584.
45. Wallis A.B., Saftlas A.F., Hsia J., Atrash H.K. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens 2008, 21:521-526.
46. Bramham K., Nelson-Piercy C., Brown M.J., Chappell L.C. Postpartum management of hypertension. BMJ 2013, 346:f894.
47. Bellamy L., Casas J.P., Hingorani A.D., Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009, 373:1773-1779.
48. Bellamy L., Casas J.P., Hingorani A.D., Williams D.J. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007, 335:974.
49. Lykke J.A., Langhoff-Roos J., Sibai B.M., et al. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension 2009, 53:944-951.
50. Feig D.S., Shah B.R., Lipscombe L.L., et al. Preeclampsia as a risk factor for diabetes: a population-based cohort study. PLoS Med 2013, 10:e1001425.
51. Carr D.B., Newton K.M., Utzschneider K.M., et al. Preeclampsia and risk of developing subsequent diabetes. Hypertens Pregnancy 2009, 28:435-447.
52. Engeland A., Bjorge T., Daltveit A.K., et al. Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway. Eur J Epidemiol 2011, 26:157-163.
53. Pirkola J., Pouta A., Bloigu A., et al. Prepregnancy overweight and gestational diabetes as determinants of subsequent diabetes and hypertension after 20-year follow-up. JClin Endocrinol Metab 2010, 95:772-778.
54. Yoshioka M., Doucet E., St-Pierre S., et al. Impact of high-intensity exercise on energy expenditure, lipid oxidation and body fatness. Int J Obes Relat Metab Disord 2001, 25:332-339.
55. McDonald S.D., Malinowski A., Zhou Q., Yusuf S., Devereaux P.J. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 2008, 156:918-930.
56. Mongraw-Chaffin M.L., Cirillo P.M., Cohn B.A. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension 2010, 56:166-171.
57. Ray J.G., Vermeulen M.J., Schull M.J., Redelmeier D.A. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 2005, 366:1797-1803.
58. Fraser A., Nelson S.M., Macdonald-Wallis C., et al. Associations of pregnancy complications with calculated cardiovascular disease risk and cardiovascular risk factors in middle age: the Avon Longitudinal Study of Parents and Children. Circulation 2012, 125:1367-1380.
59. Brown M.C., Best K.E., Pearce M.S., et al. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol 2013, 28:1-19.
60. Carr D.B., Utzschneider K.M., Hull R.L., et al. Gestational diabetes mellitus increases the risk of cardiovascular disease in women with a family history of type 2 diabetes. Diabetes Care 2006, 29:2078-2083.
61. Shah B.R., Retnakaran R., Booth G.L. Increased risk of cardiovascular disease in young women following gestational diabetes mellitus. Diabetes Care 2008, 31:1668-1669.
62. Freire C.M., Barbosa F.B., de Almeida M.C., et al. Previous gestational diabetes is independently associated with increased carotid intima-media thickness, similarly to metabolic syndrome - a case control study. Cardiovasc Diabetol 2012, 11:59.
63. Funk S.D., Yurdagul A., Orr A.W. Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes. Int J Vasc Med 2012, 2012:569654.
64. Berks D., Hoedjes M., Raat H., et al. Risk of cardiovascular disease after pre-eclampsia and the effect of lifestyle interventions: a literature-based study. BJOG 2013, 120:924-931.
65. Wen S.W., Xie R.H., Tan H., et al. Preeclampsia and gestational diabetes mellitus: pre-conception origins?. Med Hypotheses 2012, 79:120-125.
66. Wing R.R., Bolin P., Brancati F.L., et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. NEngl J Med 2013, 369:145-154.
67. Tuomilehto J., Lindstrõm J., Eriksson J., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. NEngl J Med 2001, 344:1343-1350.
68. Knowler W., Barrett-Connor E., Fowler S., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. NEngl J Med 2002, 346:393-403.
69. Ramachandran A., Snehalatha C., Mary S., et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006, 49:289-297.
70. Kosaka K., Noda M., Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 2005, 67:152-162.
71. Ratner R.E., Christophi C.A., Metzger B.E., et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. JClin Endocrinol Metab 2008, 93:4774-4779.
72. England L.J., Dietz P.M., Njoroge T., et al. Preventing type 2 diabetes: public health implications for women with a history of gestational diabetes mellitus. Am J Obstet Gynecol 2009, 200:365-368.
73. Smith G.N., Pudwell J., Walker M., Wen S.W. Ten-year, thirty-year, and lifetime cardiovascular disease risk estimates following a pregnancy complicated by preeclampsia. JObstet Gynaecol Can 2012, 34:830-835.
74. Grundy S.M., Pasternak R., Greenland P., Smith S., Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999, 100:1481-1492.
75. Mosca L., Benjamin E.J., Berra K., et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation 2011, 123:1243-1262.
76. Shea A.K., Shah B.R., Clark H.D., et al. The effectiveness of implementing a reminder system into routine clinical practice: does it increase postpartum screening in women with gestational diabetes?. Chronic Dis Can 2011, 31:58-64.
77. MacDonald S.E., Walker M., Ramshaw H., et al. Hypertensive disorders of pregnancy and long-term risk of hypertension: what do Ontario prenatal care providers know, and what do they communicate?. JObstet Gynaecol Can 2007, 29:705-710.
78. Jones E.J., Appel S.J., Eaves Y.D., et al. Cardiometabolic risk, knowledge, risk perception, and self-efficacy among American Indian women with previous gestational diabetes. JObstet Gynecol Neonatal Nurs 2012, 41:246-257.
79. Clark H.D., van W.C., Code C., Karovitch A., Keely E. Did publication of a clinical practice guideline recommendation to screen for type 2 diabetes in women with gestational diabetes change practice?. Diabetes Care 2003, 26:265-268.
80. Dietz P.M., Vesco K.K., Callaghan W.M., et al. Postpartum screening for diabetes after a gestational diabetes mellitus-affected pregnancy. Obstet Gynecol 2008, 112:868-874.
81. Morrison M.K., Collins C.E., Lowe J.M. Postnatal testing for diabetes in Australian women following gestational diabetes mellitus. Aust N Z J Obstet Gynaecol 2009, 49:494-498.
82. Pridjian G., Benjamin T.D. Update on gestational diabetes. Obstet Gynecol Clin North Am 2010, 37:255-267.
83. Kim C., McEwen L.N., Piette J.D., et al. Risk perception for diabetes among women with histories of gestational diabetes mellitus. Diabetes Care 2007, 30:2281-2286.
84. Yun S., Kabeer N.H., Zhu B.P., Brownson R.C. Modifiable risk factors for developing diabetes among women with previous gestational diabetes. Prev Chronic Dis 2007, 4:A07.
85. Brownson R., Baker E., Housemann R., Brennan L., Bacak S. Environmental and policy determinants of physical activity in the United States. Am J Public Health 2001, 91:1995-2003.
86. Bryan S., Walsh P. Physical activity and obesity in Canadian women. BMC Womens Health 2004, 25(4 suppl 1):S6.
87. King A., Castro C., Wilcox S., et al. Personal and environmental factors associated with physical inactivity among different racial-ethnic groups of U.S. middle-aged and older-aged women. Health Psychol 2000, 19:354-364.
88. Chen J., Millar W. Starting and sustaining physical activity. Health Rep 2001, 12:33-43.
89. Graco M., Garrard J., Jasper A.E. Participation in physical activity: perceptions of women with a previous history of gestational diabetes mellitus. Health Promot J Austr 2009, 20:20-25.
90. Zehle K., Smith B.J., Chey T., et al. Psychosocial factors related to diet among women with recent gestational diabetes: opportunities for intervention. Diabetes Educ 2008, 34:807-814.
91. Ostbye T., Krause K.M., Lovelady C.A., et al. Active Mothers Postpartum: a randomized controlled weight-loss intervention trial. Am J Prev Med 2009, 37:173-180.
92. Ferrara A., Hedderson M.M., Albright C.L., et al. Apregnancy and postpartum lifestyle intervention in women with gestational diabetes mellitus reduces diabetes risk factors: a feasibility randomized control trial. Diabetes Care 2011, 34:1519-1525.
93. Hoedjes M., Berks D., Vogel I., et al. Preferences for postpartum lifestyle counseling among women sharing an increased cardiovascular and metabolic risk: a focus group study. Hypertens Pregnancy 2011, 30:83-92.
94. Dasgupta K., Da C.D., Pillay S., et al. Strategies to optimize participation in diabetes prevention programs following gestational diabetes: a focus group study. PLoS One 2013, 8:e67878.
95. Dasgupta K., Hajna S., Joseph L., et al. Effects of meal preparation training on body weight, glycemia, and blood pressure: results of a phase 2 trial in type 2 diabetes. Int J Behav Nutr Phys Act 2012, 9:125.
96. Nicklas J.M., Zera C.A., Seely E.W., et al. Identifying postpartum intervention approaches to prevent type 2 diabetes in women with a history of gestational diabetes. BMC Pregnancy Childbirth 2011, 11:23.